Literature DB >> 10443965

Lipoprotein (a) metabolism estimated by nonsteady-state kinetics.

K G Parhofer1, T Demant, M M Ritter, H C Geiss, M Donner, P Schwandt.   

Abstract

Lipoprotein (a) [Lp(a)] is a low-density lipoprotein (LDL) particle with an additional apolipoprotein named apo(a). The concentration of Lp(a) in plasma is determined to a large extent by the size of the apo(a) isoform. Because elevated Lp(a) concentrations in plasma are associated with risk for premature coronary heart disease it is important to determine whether variations in production or catabolism mediate differences in Lp(a) concentration. We determined metabolic parameters of Lp(a) in 17 patients with heterozygous familial hypercholesterolemia or severe mixed hyperlipidemia by fitting a monoexponential function to the rebound of Lp(a) plasma concentration following LDL-apheresis. In 8 of those 17 patients this was done twice following two different aphereses. Although this approach allows one to estimate metabolic parameters without the use of a tracer, it requires several major assumptions such as that apheresis itself does not change production or catabolism of Lp(a) and that Lp(a) metabolism can be described by a single compartment. One apheresis decreased Lp(a) concentration by 59.1+/-8.3%. The fractional catabolic rate (FCR) was 0.16+/-0.12 d(-1) and production rate 6.27+/-5.26 mg x kg(-1) x d(-1). However, observed (concentration before first apheresis) and predicted steady-state concentrations differed considerably (more than 20%) in 9 of 17 patients, indicating that not all assumptions were fulfilled in all patients. Production rate but not FCR was correlated with Lp(a) plasma concentration (r2 = 0.43, P = 0.004) and molecular weight of apo(a) (r2 = 0.48, P = 0.011), which confirms radiotracer experiments showing that variations in Lp(a) plasma concentrations are due to differences in production not catabolism. When parameters were estimated twice in a subgroup of eight patients, satisfactory reproducibility was observed in six patients. Although parameters determined on two occasions correlated well, only FCR was concordant (intraclass correlation coefficient). Thus, despite the limitations arising from the assumptions implicit to this method, metabolic parameters of Lp(a) can be estimated from the rebound of plasma concentration following apheresis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10443965     DOI: 10.1007/s11745-999-0370-z

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  20 in total

1.  Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation.

Authors:  F Kronenberg; E Trenkwalder; A Lingenhel; G Friedrich; K Lhotta; M Schober; N Moes; P König; G Utermann; H Dieplinger
Journal:  J Lipid Res       Date:  1997-09       Impact factor: 5.922

2.  Low-density lipoprotein-apolipoprotein B metabolism following apheresis: simulation studies of mass changes and tracer kinetics.

Authors:  P H Barrett; K G Parhofer
Journal:  Metabolism       Date:  1998-04       Impact factor: 8.694

3.  Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a].

Authors:  J W Gaubatz; K I Ghanem; J Guevara; M L Nava; W Patsch; J D Morrisett
Journal:  J Lipid Res       Date:  1990-04       Impact factor: 5.922

4.  Apolipoprotein E polymorphism has no independent effect on plasma levels of lipoprotein(a).

Authors:  M M Ritter; J Gewitsch; W O Richter; H C Geiss; M W Wildner; P Schwandt
Journal:  Atherosclerosis       Date:  1997-06       Impact factor: 5.162

5.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.

Authors:  G Utermann; H J Menzel; H G Kraft; H C Duba; H G Kemmler; C Seitz
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

6.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

7.  Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels.

Authors:  V W Armstrong; J Schleef; J Thiery; R Muche; P Schuff-Werner; T Eisenhauer; D Seidel
Journal:  Eur J Clin Invest       Date:  1989-06       Impact factor: 4.686

8.  Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia.

Authors:  K G Parhofer; P H Barrett; T Demant; W O Richter; P Schwandt
Journal:  J Lipid Res       Date:  1996-11       Impact factor: 5.922

9.  Lipoprotein(a) concentrations and phenotypes in controls and patients with hypercholesterolemia or hypertriglyceridemia.

Authors:  M M Ritter; H C Geiss; W O Richter; P Schwandt
Journal:  Metabolism       Date:  1994-05       Impact factor: 8.694

10.  The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.

Authors:  D J Rader; W A Mann; W Cain; H G Kraft; D Usher; L A Zech; J M Hoeg; J Davignon; P Lupien; M Grossman
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more
  6 in total

Review 1.  Lipoprotein apheresis to treat elevated lipoprotein (a).

Authors:  Elisa Waldmann; Klaus G Parhofer
Journal:  J Lipid Res       Date:  2016-02-17       Impact factor: 5.922

2.  Familial hypercholesterolaemia.

Authors:  A David Marais
Journal:  Clin Biochem Rev       Date:  2004-02

Review 3.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

4.  Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects.

Authors:  Renu Nandakumar; Anastasiya Matveyenko; Tiffany Thomas; Marianna Pavlyha; Colleen Ngai; Stephen Holleran; Rajasekhar Ramakrishnan; Henry N Ginsberg; Wahida Karmally; Santica M Marcovina; Gissette Reyes-Soffer
Journal:  J Lipid Res       Date:  2018-10-07       Impact factor: 5.922

5.  Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Authors:  Gissette Reyes-Soffer; Marianna Pavlyha; Colleen Ngai; Tiffany Thomas; Stephen Holleran; Rajasekhar Ramakrishnan; Wahida Karmally; Renu Nandakumar; Nelson Fontanez; Joseph Obunike; Santica M Marcovina; Alice H Lichtenstein; Nirupa R Matthan; James Matta; Magali Maroccia; Frederic Becue; Franck Poitiers; Brian Swanson; Lisa Cowan; William J Sasiela; Howard K Surks; Henry N Ginsberg
Journal:  Circulation       Date:  2016-12-16       Impact factor: 29.690

Review 6.  The metabolism of lipoprotein (a): an ever-evolving story.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2017-07-18       Impact factor: 5.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.